Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer immunotherapy, including Merck & Co. The US regulator cleared BMS' LAG-3 drug relatlimab as a ...
The market regulator has proposed a uniform 30-day delay in using price data for investor education to remove regulatory ...
Variable names are alphanumeric but must start with a letter. The length of a variable name is limited to thirty-two characters for non-SAS data set variables Model variables are declared by VAR, ...
The move is aimed at preventing misuse of market data while ensuring that educational content remains useful and relevant for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback